In this study, inhibition of NF-κB nuclear translocation together with the down-regulation of its target Bcl-2 family member genes suggested that activation of NF-κB was inhibited by oridonin during tumor progression (Figure 5A). The gene discussed is BCL2; the disease is neoplasm.